Last reviewed · How we verify
Nicotinamide treatment
Nicotinamide replenishes NAD+ cofactor pools to support cellular energy metabolism and DNA repair pathways.
Nicotinamide replenishes NAD+ cofactor pools to support cellular energy metabolism and DNA repair pathways. Used for Phase 3 indication not publicly specified; likely dermatologic or metabolic condition based on nicotinamide's known clinical applications.
At a glance
| Generic name | Nicotinamide treatment |
|---|---|
| Also known as | NICOBION |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Vitamin B3 / NAD+ precursor |
| Target | NAD+ biosynthesis pathway |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Nicotinamide (vitamin B3) is a precursor to nicotinamide adenine dinucleotide (NAD+), a critical coenzyme involved in energy production, DNA repair, and cellular stress responses. By increasing intracellular NAD+ levels, nicotinamide treatment may enhance mitochondrial function and activate sirtuins and PARPs, proteins involved in genomic stability and cellular resilience. This mechanism has been explored in conditions characterized by impaired cellular energy metabolism or DNA damage.
Approved indications
- Phase 3 indication not publicly specified; likely dermatologic or metabolic condition based on nicotinamide's known clinical applications
Common side effects
- Nausea
- Flushing
- Hyperglycemia
- Hepatotoxicity (at high doses)
Key clinical trials
- Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma (PHASE1)
- Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate (NA)
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (PHASE1)
- MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib (PHASE3)
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (PHASE3)
- Phase 2 Study of WGI-0301 for Advanced HCC (PHASE2)
- A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC (PHASE3)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicotinamide treatment CI brief — competitive landscape report
- Nicotinamide treatment updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI